Search Clinical Trials in the European Union

Duration
Visits
Confirmation phase (III)
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
1-20 of 1,307 trials

Adrenocortical Carcinoma: Mitotane Treatment Study

We are comparing standard mitotane therapy to mitotane combined with chemotherapy for patients at high risk of cancer recurrence after surgery. This study aims to find out which treatment helps patients live longer and maintain a better quality of life.

Adrenocortical Carcinoma6-12 monthsConfirmation phase (III)No PlaceboStandard MedicinesOncology

Hodgkin Lymphoma: A2VD vs. ABVD Treatment Study

We are comparing two treatment options for patients with untreated early-stage Hodgkin lymphoma to see which may improve survival and reduce side effects. This study uses advanced imaging techniques to guide treatment decisions.

Classical Hodgkin LymphomaConfirmation phase (III)No PlaceboStandard MedicinesOncology

Nalmefene for Reducing Cravings in Behavioral Addictions

We are studying whether nalmefene can help reduce craving intensity in people with behavioral addictions, such as gambling and food addiction, when added to their usual treatment.

Behavioural AddictionConfirmation phase (III)≤5 visitsStandard MedicinesCost Reimbursement

FORE-PAIN Trial: Pain Relief Options for Trauma

We are studying whether intranasal and intravenous forms of fentanyl and esketamine can effectively relieve acute traumatic pain. The goal is to see if these options are as safe and satisfying as traditional intravenous fentanyl.

Acute Traumatic PainConfirmation phase (III)No PlaceboInvestigational MedicinesInternal MedicineOtolaryngologyPsychiatry

Cardiac AL Amyloidosis: [18F]florbetaben PET Imaging Study

We are evaluating a new imaging technique to improve the diagnosis of cardiac AL amyloidosis in patients. This study will help us understand how well it works compared to current diagnostic methods.

Cardiac AmyloidosisAL AmyloidosisATTR Amyloidosis>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesCardiologyInternal Medicine

Hydrochlorothiazide for Polycystic Kidney Disease Patients

We are studying whether adding hydrochlorothiazide to tolvaptan can help slow kidney function decline in people with polycystic kidney disease. This trial also looks at how this combination affects quality of life and treatment tolerability.

Autosomal Dominant Polycystic Kidney Disease>2 yearsConfirmation phase (III)≤5 visitsStandard MedicinesPartially RemoteInternal MedicineNephrology

Rheumatoid Arthritis: Abatacept vs. TNF Inhibitors

We are comparing a new treatment strategy using abatacept to the standard TNF inhibitors for patients with rheumatoid arthritis. The goal is to see which approach helps more patients achieve remission.

Rheumatoid Arthritis6-12 monthsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesInternal MedicineRheumatology

Diabetic Foot Infections: Contezolid Treatment Study

We are studying a new treatment called contezolid for adults with moderate to severe diabetic foot infections. The goal is to see if it is safer and more effective than the current standard treatment, linezolid.

Diabetic Foot Infection≤3 monthsConfirmation phase (III)6-10 visitsInvestigational MedicinesCost ReimbursementPartially RemoteEndocrinologyInfectious Diseases

Chronic Pain in Children: Capsaicin Patch Study

We are investigating whether a capsaicin patch can help relieve chronic pain in children aged 12 to 17 after surgery or injury. The study will also look at how well the treatment is tolerated and its effects on other pain medications.

Chronic Neuropathic Pain3-6 monthsConfirmation phase (III)Investigational MedicinesNeurologyPediatrics

Epidermolysis Bullosa: ABCB5+ Stem Cell Treatment

We are studying a new stem cell therapy for individuals with recessive dystrophic epidermolysis bullosa. The trial aims to see if this treatment is safe and effective compared to a placebo.

Epidermolysis Bullosa1-2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteDermatologyInternal Medicine

End-Stage Kidney Disease: CSL300 Treatment Study

We are investigating whether different doses of CSL300 can help reduce inflammation in adults with end-stage kidney disease undergoing dialysis. This study aims to understand its potential effects on heart health.

Atherosclerotic Cardiovascular Disease1-2 yearsEfficacy phase (II)Confirmation phase (III)>20 visitsInvestigational MedicinesCost ReimbursementCardiologyInternal MedicineNephrology

Uveal Melanoma: Adjuvant Melatonin Study

We are investigating whether nightly melatonin can help reduce the spread of uveal melanoma and improve survival rates. This study is for patients diagnosed with this type of eye cancer.

Uveal MelanomaConfirmation phase (III)No PlaceboStandard MedicinesOncologyOphthalmology

Risankizumab for Moderate to Severe Plaque Psoriasis in Children and Teens

We are studying the long-term safety and effectiveness of risankizumab in children and teens aged 6 to 17 with moderate to severe plaque psoriasis. This follows their participation in a previous study to see how well the treatment works over time.

Plaque Psoriasis>2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesAllergologyDermatology

Cardiac Surgery: Vasopressin vs. Norepinephrine

We are comparing two medications to see which better protects kidney function and reduces complications in patients at risk during cardiac surgery. This study aims to improve outcomes for those undergoing surgery with heart-lung machines.

Vasoplegic Syndrome>2 yearsConfirmation phase (III)No PlaceboInvestigational MedicinesCardiologyInternal MedicineNephrologyOtolaryngology

Anemia in Low-Risk Myelodysplastic Syndrome: Luspatercept vs Epoetin Alfa

We are comparing a new treatment, luspatercept, with a standard treatment, epoetin alfa, for patients with low-risk myelodysplastic syndrome who do not need blood transfusions. The goal is to see which treatment better helps manage anemia.

Myelodysplastic Syndrome (MDS)>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteHematologyInternal Medicine

Glioblastoma: Early Intensified Treatment with Temozolomide

We are studying whether starting chemotherapy earlier with temozolomide helps adults with glioblastoma live longer compared to standard treatment. The trial also examines safety and treatment effectiveness.

Glioblastoma>2 yearsConfirmation phase (III)11-15 visitsNo PlaceboStandard MedicinesNeurologyOncology

Prostate Cancer: Abemaciclib with Abiraterone

We are studying whether adding abemaciclib to standard treatment improves outcomes for men with prostate cancer that has spread and is responsive to hormonal therapy. The trial also evaluates safety and patient quality of life.

High-Risk Metastatic Hormone-Sensitive Prostate CancerConfirmation phase (III)Post-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Marstacimab for Severe Hemophilia A and B

We are studying the long-term safety and effectiveness of marstacimab in people aged 1 to 75 with severe hemophilia A or B, with or without inhibitors. This research aims to improve treatment options for managing this condition.

Haemophilia>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteHematology

Myelodysplastic Syndrome: Oral Azacitidine Study

We are studying whether Oral Azacitidine, combined with best supportive care, is more effective than a placebo for patients with low- or intermediate-risk MDS. The goal is to see if it improves blood counts and reduces the need for blood transfusions.

Myelodysplastic Syndromes (MDS)>2 yearsEfficacy phase (II)Confirmation phase (III)>20 visitsPost-Trial Drug AccessStandard MedicinesHematology

Fabry Disease: Migalastat for Kidney Impairment

We are studying the safety and how the body processes migalastat in people with Fabry disease and severe kidney impairment on dialysis. This research aims to ensure the right dosing for these patients.

Fabry Disease>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesHematologyInternal MedicineNephrology